I5161
ヨードアセトアミド
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
化学式:
ICH2CONH2
CAS番号:
分子量:
184.96
EC Number:
205-630-1
UNSPSC Code:
12352202
NACRES:
NA.21
Beilstein/REAXYS Number:
1739080
MDL number:
biological source
synthetic
Quality Level
assay
≥99% (NMR)
form
powder
mp
92-95 °C (lit.)
solubility
H2O: 0.5 M, clear, colorless
suitability
suitable for manufacturing use
storage temp.
2-8°C
SMILES string
NC(=O)CI
InChI
1S/C2H4INO/c3-1-2(4)5/h1H2,(H2,4,5)
InChI key
PGLTVOMIXTUURA-UHFFFAOYSA-N
General description
Our SAFC® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity Program.
M-Clarity Program
Our comprehensive portfolio of upstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Trust us to deliver supply chain transparency and reliable sourcing around the globe, streamlining your product qualification with best-in-class regulatory support and service.
M-Clarity Program
Our comprehensive portfolio of upstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Trust us to deliver supply chain transparency and reliable sourcing around the globe, streamlining your product qualification with best-in-class regulatory support and service.
Biochem/physiol Actions
ヨードアセトアミドは、ペプチドシーケンシングにおけるシステイン残基のアルキル化試薬として機能します。活性部位にシステインを有する酵素の不可逆阻害剤です。ヒスチジン残基との反応速度はかなり遅くなりますが、その活性はリボヌクレアーゼの阻害に関与しています。
Legal Information
SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under ヨードアセトアミド
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Aquatic Chronic 4 - Resp. Sens. 1 - Skin Sens. 1
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
名称等を表示すべき危険物及び有害物
ishl_indicated
名称等を通知すべき危険物及び有害物
ishl_notified
I5161-25G:4.548173372693E12
jan
Valentina R Minciacchi et al.
Oncotarget, 6(13), 11327-11341 (2015-04-11)
Large oncosomes (LO) are atypically large (1-10 µm diameter) cancer-derived extracellular vesicles (EVs), originating from the shedding of membrane blebs and associated with advanced disease. We report that 25% of the proteins, identified by a quantitative proteomics analysis, are differentially
Mia Jüllig et al.
PloS one, 9(5), e96489-e96489 (2014-05-08)
Bypass of foregut secreted factors promoting insulin resistance is hypothesized to be one of the mechanisms by which resolution of type 2 diabetes (T2D) follows roux-en-y gastric bypass (GBP) surgery. To identify insulin resistance-associated proteins and metabolites which decrease more
Jeremy Rouillon et al.
Neuromuscular disorders : NMD, 24(7), 563-573 (2014-05-13)
Diagnosis of muscular dystrophies is currently based on invasive methods requiring muscle biopsies or blood tests. The aim of the present study was to identify urinary biomarkers as a diagnostic tool for muscular dystrophies. Here, the urinary proteomes of Duchenne